Literature DB >> 23150619

Pharmacokinetics of ocriplasmin in vitreous.

Marc D de Smet1, Bart Jonckx, Marc Vanhove, Joachim van Calster, Peter Stalmans, Jean Marie Stassen.   

Abstract

PURPOSE: Ocriplasmin contains the active moiety of plasmin enzyme. At a physiologic pH, ocriplasmin is highly proteolytic and autolytic, limiting its duration of activity. Specific inhibitors of plasmin are present in the vitreous under normal and disease conditions and could affect its activity. Each may contribute to its mode of action.
METHODS: Degradation characteristics were determined in porcine, human vitreous, and PBS under reducing conditions with different incubation periods between 0 and 24 hours on SDS-PAGE Tris-glycine gels. Residual activity was determined by spectrophotometry of p-nitroaniline release through hydrolysis of L-pyroglutamyl-L-phenylalanyl-L-lysine-p-nitroaniline hydrochloride. The presence of endogenous inactivators of ocriplasmin in human vitreous was determined in a series of vitreous samples using an ELISA specific for alpha(2)-antiplasmin, antithrombin, and antitrypsin.
RESULTS: Degradation productions from autolysis are similar between vitreous and PBS with a significant prolongation of the effect in vitreous. Both follow a nonlinear pattern over time. The degradation corresponds best to a second-order kinetic process. The resulting rate constants were 207 ± 60 M(-1) s(-1) in PBS, 81 ± 15 M(-1) s(-1) in porcine vitreous, and 195 M(-1) s(-1) in human vitreous natural inhibitors were identified in samples of donor vitreous. Amounts differed significantly between samples, which may help explain the observed variability in human subjects.
CONCLUSIONS: Ocriplasmin is autolytic in vitreous. Biologic activity extends to several days following injection. The exact duration will vary based on the presence and concentration of serine protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23150619     DOI: 10.1167/iovs.12-10148

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Ocriplasmin - variable efficacy?

Authors:  David H W Steel; David Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-04       Impact factor: 3.117

2.  Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.

Authors:  Irini Chatziralli; George Theodossiadis; Efstratios Parikakis; Ioannis Datseris; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-05       Impact factor: 3.117

Review 3.  Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Authors:  Irini Chatziralli; George Theodossiadis; Paraskevi Xanthopoulou; Michael Miligkos; Sobha Sivaprasad; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-30       Impact factor: 3.117

Review 4.  Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion.

Authors:  Yahiya Y Syed; Sohita Dhillon
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

5.  Engineering of Ocriplasmin Variants by Bioinformatics Methods for the Reduction of Proteolytic and Autolytic Activities.

Authors:  Roghayyeh Baghban; Safar Farajnia; Younes Ghasemi; Mojtaba Mortazavi; Samaneh Ghasemali; Mostafa Zakariazadeh; Nosratollah Zarghami; Nasser Samadi
Journal:  Iran J Med Sci       Date:  2021-11

6.  Retinal breaks due to intravitreal ocriplasmin.

Authors:  Ruwan A Silva; Darius M Moshfeghi; Theodore Leng
Journal:  Clin Ophthalmol       Date:  2014-08-25

7.  Comparison of Guided and Unguided Ocriplasmin Injection for the Treatment of Vitreomacular Traction: A Preliminary Study.

Authors:  Rodolfo Mastropasqua; Luca Di Antonio; Vincenzo Ciciarelli; Agbeanda Aharrh-Gnama; Marco Rispoli; Paolo Carpineto
Journal:  J Ophthalmol       Date:  2016-03-15       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.